Plain-English translation of NCT04857502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging medication called 99mTc-PSMA-I&S that helps surgeons see where prostate cancer is located in your body. The medication is injected into your bloodstream and shows up on special imaging scans, making cancer cells easier to spot during surgery. Researchers want to understand how this medication moves through your body and when it works best for guiding surgeons to remove cancer.
Current ways of finding prostate cancer during surgery aren't always precise enough, which can mean some cancer is missed or healthy tissue is removed unnecessarily. This study aims to improve surgery outcomes by finding the best way to use this medication to light up cancer cells so surgeons can remove them more completely.
You likely qualify if…
You likely don't qualify if…
The first 5 participants will receive an injection of the medication and then return for five imaging scans over about 2 weeks to show researchers how the medication travels through the body and when it works best. All participants will receive another dose of the medication right before their standard prostate cancer surgery. The medication helps surgeons see cancer cells during the operation and may help them remove cancer more completely.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States